Tavotek Biotherapeutics

Executive Summary

Tavotek Biotherapeutics is a privately held, early-stage biotechnology company pioneering next-generation multi-specific antibodies for oncology and autoimmune diseases. Founded in 2018 and headquartered in Philadelphia, the company leverages its proprietary platforms to design novel biologic therapies with improved specificity and efficacy. While still in the preclinical and early clinical stages, Tavotek's pipeline targets validated pathways with potential for best-in-class profiles. The company's scientific approach and experienced management team position it to address significant unmet medical needs, though it faces typical early-stage risks including clinical validation, regulatory hurdles, and financing requirements.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Multi-Specific Antibody40% success
• Q4 2026Initial Phase 1 Data from Oncology Program30% success
• TBDStrategic Partnership or Licensing Deal25% success